Nonpeptide oxytocin agonists

被引:12
作者
Ashworth, Doreen M.
Batt, Andrzej R.
Baxter, Andrew J.
Broqua, Pierre
Haigh, Robert M.
Hudson, Peter
Heeney, Celine M. S.
Laporte, Regent
Penson, Andrew
Pitt, Gary R. W.
Robson, Peter A.
Rooker, David P.
Tartar, Andre L.
Yea, Chris M.
Roe, Michael B.
机构
[1] Ferring Res Ltd, Southampton SO16 7NP, Hants, England
[2] Ferring Pharmaceut AS, DK-2300 Copenhagen S, Denmark
[3] Ferring Res Inst Inc, San Diego, CA 92121 USA
[4] Fac Sci Pharmaceut & Biol, F-59006 Lille, France
关键词
D O I
10.1358/dof.2006.031.04.980655
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oxytocin is a neurohypophyseal hormone that acts at the oxytocin receptor localized both peripherally and centrally and is particularly highly expressed in the pregnant human myometrium. Synthetic oxytocin has long been used to induce labor and oxytocin antagonists have been introduced for the treatment of preterm labor. New compounds are described that are potent, selective and efficacious oxytocin receptor agonists with potential utility in promoting labor and for the treatment of conditions such as male and female sexual dysfunction. These new agents may also be useful as tools for further elucidating the roles of the oxytocin receptor system. Furthermore, as they are nonpeptidic in nature, they may offer advantages over peptide oxytocin analogues in terms of oral availability and central penetration. This article describes the various approaches that have been used to discover such compounds. Compounds such as 27, the first nonpeptide oxytocin agonists reported, are currently being investigated as pharmacological tools in animal models of oxytocin activity.
引用
收藏
页码:345 / 353
页数:9
相关论文
共 26 条
  • [11] Freidinger RM, 1997, MED RES REV, V17, P1, DOI 10.1002/(SICI)1098-1128(199701)17:1<1::AID-MED1>3.0.CO
  • [12] 2-5
  • [13] ENDOCRINOLOGY OF HUMAN PARTURITION - A REVIEW
    FUCHS, AR
    FUCHS, F
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1984, 91 (10): : 948 - 967
  • [14] The Oxytocin Receptor System: Structure, function, and regulation
    Gimpl, G
    Fahrenholz, F
    [J]. PHYSIOLOGICAL REVIEWS, 2001, 81 (02) : 629 - 683
  • [15] LEWIS R, 1999, 94 ANN M AM UR ASS M
  • [16] Privileged structures - An update
    Patchett, AA
    Nargund, RP
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 35, 2000, 35 : 289 - 298
  • [17] PITT GR, 2001, RSC SCI S MED CHEM S
  • [18] Non-peptide oxytocin agonists
    Pitt, GRW
    Batt, AR
    Haigh, RM
    Penson, AM
    Robson, PA
    Rooker, DP
    Tartar, AL
    Trim, JE
    Yea, CM
    Roe, MB
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (17) : 4585 - 4589
  • [19] Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V-2 vasopressin receptor
    Postina, R
    Kojro, E
    Fahrenholz, F
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (49) : 31593 - 31601
  • [20] Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists
    Quattropani, A
    Dorbais, J
    Covini, D
    Pittet, PA
    Colovray, V
    Thomas, RJ
    Coxhead, R
    Halazy, S
    Scheer, A
    Missotten, M
    Ayala, G
    Bradshaw, C
    De Raemy-Schenk, AM
    Nichols, A
    Cirillo, R
    Tos, EG
    Giachetti, C
    Golzio, L
    Marinelli, P
    Church, DJ
    Barberis, C
    Chollet, A
    Schwarz, MK
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (24) : 7882 - 7905